We systematically reviewed the security and effectiveness of cannabis and cannabinoids therapy for Crohn’s illness (CD) and ulcerative colitis (UC).
MEDLINE, Embase, WHO ICTRP, AMED, PsychINFO, CENTRAL, ClinicalTrials.Gov, and the European Clinical Trials Register had been searched for relevant research.
5 randomized controlled trials (three CD and two UC research, 185 participants) had been incorporated. 1 CD study (N = 21) showed 45% (five of 11) of the cannabis cigarette group knowledgeable clinical remission compared with 10% (1 of 10) of the placebo group (threat ratio [RR] four.55 95% CI, .63–32.56). A different CD study (N = 19) did not show considerable prices of clinical remission. Forty % (four of 10) of participants in the cannabis oil group knowledgeable remission compared with 33% (three of 9) of the placebo group (RR 1.20 95% CI, .36–3.97). A UC study (N = 60) did not have considerable clinical remission prices. Twenty-4 % (7 of 29) of cannabis oil participants knowledgeable remission compared with 26% (eight of 31) of placebo participants (RR .94 95% CI, .39–2.25). A second UC study (N = 32) showed the effects on illness activity, C-reactive protein levels, and fecal calprotectin levels had been uncertain. Adverse events had been much more prevalent in the cannabis groups for each CD and UC research. GRADE evaluation for the UC and CD research ranged from incredibly low to moderate.
In summary, no firm conclusions can be created with regards to the security and effectiveness of cannabis and cannabinoids in adults with CD and UC.
© 2019 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: [email protected]